FTRE

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

Wall Street analysts forecast FTRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTRE is 11.19 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fortrea Holdings Inc revenue for the last quarter amounts to 701.30M USD, increased 3.91 % YoY.

Fortrea Holdings Inc. EPS for the last quarter amounts to -0.17 USD, decreased -45.16 % YoY.

Fortrea Holdings Inc (FTRE) has 15500 emplpoyees as of December 15 2025.

Today FTRE has the market capitalization of 1.45B USD.